[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
Sep 24, 2012

Behavioral Medicine Trial Design: Time for a Change—Reply

Arch Intern Med. 2012;172(17):1350-1351. doi:10.1001/archinternmed.2012.3223

In reply

We wish to thank Lavoie and colleagues for their thoughtful letter. We agree with their suggestion that interventions in behavioral medicine be viewed analogously to phase 1, 2, and 3 clinical trials in drug development and thank them for pointing out the recommendations of the Office of Behavioral and Social Science Research.